LXRX News and Press, Lexicon Pharmaceuticals Inc. From 03/02/23

NDA for Sotagliflozin on Track for May 2023 PDUFA date following Late-Cycle Review Meeting LX9211 Demonstrates Consistent Results in Full Data from RELIEF-DPN-1 in Diabetic Peripheral Neuropathic Pain and Top-Line Data from RELIEF-PHN-1 in Post-Herpetic Neuralgia Confere...

THE WOODLANDS, Texas, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its fourth quarter 2022 financial results on Thursday, March 2, 2023 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00...

THE WOODLANDS, Texas, Feb. 20, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced the upcoming presentation of new analyses of results from the SOLOIST-WHF Phase 3 outcomes study of its investigational sotagliflozin product at the American College of Ca...

THE WOODLANDS, Texas, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the 41 st Annual JP Morgan Healthcare Conference, taking place January 9-12, 2023. Lonnel Coats, Lexicon’s chief executive officer, will m...

Summary I discuss Lexicon's long and tumultuous history. Sotagliflozin has a PDUFA in May 2023 for a heart failure indication. Maybe the company will finally prevail. This article was originally published on December 22 for TPT members. We have been covering Lexico...

Lexicon Pharmaceuticals ( NASDAQ: LXRX ) is down 11% in after-hours trading after a mid-stage trial for postherpetic neuralgia LX9211 failed to meet the primary endpoint . Although LX9211 achieved a reduction in average daily pain score 0.80 points greater than with placebo, t...

LX9211 demonstrated clear evidence of effect, achieving Lexicon’s goal for the study of supporting advancement in another indication within neuropathic pain Consistent reduction in ADPS compared to placebo throughout dosing period, statistically significant when measured acro...

Summary Lexicon shares have drifted lower since the summer, with little news of consequence to sway investor opinions. Upcoming Phase II data for LX9211 in another pain indication could further highlight the potential of this new approach to pain and strengthen the clinical and partners...

THE WOODLANDS, Texas, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the following investor conferences taking place November 29 - December 1, 2022: 34 th Annual Piper Sandler Healthcare Conference 5 ...

Achieved primary endpoint for reduction in average daily pain score (ADPS) at week 6 Significant benefits demonstrated on burning pain and on pain interference with sleep No evidence of withdrawal symptoms or rebound pain after treatment ended Conference Call...